Market Overview

UPDATE: Jefferies Raises PT on Merck & Co. on Positive Outlook

Share:
Related MRK
ALK Announces Merck Submits BLA to FDA for Investigational House Dust Mite SLIT-tablet
How To Invest In An Aging World With The 'Live Long & Prosper' ETF
Incyte Plummets After Stopping Trial Of Jakafi In Pancreatic Cancer (Investor's Business Daily)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Merck & Co. (NYSE: MRK), and raised the price target from $46.00 to $48.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Merck & Co. closed on Tuesday at $45.51.

Latest Ratings for MRK

DateFirmActionFromTo
Jan 2016Bank of AmericaDowngradesBuyNeutral
Jan 2016JefferiesMaintainsHold
Dec 2015BarclaysUpgradesEqual-weightOverweight

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (MRK)

Get Benzinga's Newsletters